Bristol-Myers Squibb

Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, focused on developing an automated platform for the production and characterization of antibodies. Founded in 2019, the company utilizes an AI-guided protein therapeutic platform that combines a wet laboratory with advanced machine learning techniques. This integrated approach enables the design of antibodies and other therapeutic proteins with enhanced biophysical properties and complex functions. BigHat Biosciences aims to create safer and more effective treatments for patients facing significant health challenges by leveraging its innovative capabilities in antibody engineering and biotherapeutic design.

Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Transition Bio, Inc. is a biotechnology company that specializes in the discovery, analysis, and modulation of biological condensates. Established in 2020 and headquartered in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom, the company has developed a unique platform known as Condensomics. This hypothesis-free drug discovery and diagnostics technology allows for expansive opportunities in drug development by leveraging the intricate properties of biological condensates. Transition Bio's innovative approach aims to advance the understanding and application of these biological structures in the field of medicine.

Sapience Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of peptide-based therapeutics aimed at treating high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company focuses on advancing innovative treatments for major unmet medical needs, particularly glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Its lead product, ST101, functions as an inhibitor of C/EBPß, a transcription factor that is often overexpressed in various cancers and plays a role in cellular differentiation, tumor survival, and proliferation. ST101 targets and reduces the expression of several genes and proteins linked to cancer cell survival and growth, inducing selective cytotoxicity across multiple tumor types, including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. Through its research, Sapience Therapeutics aims to translate scientific advancements into effective therapies that address oncogenic and immune dysregulation in cancer.

Octant Bio is focused on advancing health and treating complex diseases through innovative synthetic technology. The company utilizes a combination of synthetic biology, genome engineering, next-generation sequencing, and computational methods to assess the activity of numerous receptor pathways within human cells. This approach allows for the development of multi-targeted small molecule drug leads by leveraging machine learning to engineer compounds that interact with multiple receptors. By generating extensive multi-receptor pathway data, Octant Bio aims to enhance rational drug design and uncover new therapeutic possibilities. Founded in 2017 and based in Los Angeles, California, Octant Bio is dedicated to transforming the landscape of drug discovery and development.

Octant Bio is focused on advancing health and treating complex diseases through innovative synthetic technology. The company utilizes a combination of synthetic biology, genome engineering, next-generation sequencing, and computational methods to assess the activity of numerous receptor pathways within human cells. This approach allows for the development of multi-targeted small molecule drug leads by leveraging machine learning to engineer compounds that interact with multiple receptors. By generating extensive multi-receptor pathway data, Octant Bio aims to enhance rational drug design and uncover new therapeutic possibilities. Founded in 2017 and based in Los Angeles, California, Octant Bio is dedicated to transforming the landscape of drug discovery and development.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.

SilaGene, Inc. is a biotechnology company based in Hillsborough, New Jersey, founded in 2008. The company specializes in the development of U1 adaptors that hold therapeutic potential for various diseases, particularly in the treatment of different types of cancers. Its innovative technology serves as a gene silencing tool, which enhances the research of gene function in both cell cultures and in vivo settings. By addressing the limitations of existing gene silencing technologies, SilaGene aims to provide effective treatment options for patients.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. The company focuses on immuno-oncology, leveraging its unique computational discovery capabilities to identify novel drug targets and biological pathways for cancer therapeutics. Compugen's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT, both designed for the treatment of solid tumors. Additionally, the company has early-stage programs addressing myeloid targets and various mechanisms of immune resistance. Compugen collaborates with notable partners, including Bayer Pharma AG and Bristol-Myers Squibb, to further research and develop its therapeutics. Founded in 1993, Compugen employs a hypothesis-driven approach to drug discovery, utilizing in silico methods for product candidate prediction and validation, enhancing its ability to meet unmet therapeutic needs in the pharmaceutical and biotech sectors.

Clade Therapeutics is a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem-cell-based medicines.

Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.

Allyx Therapeutics, founded in 2018 and located in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company specializes in a therapeutic drug that is an orally bioavailable small molecule, functioning as a silent allosteric modulator of mGluR5. This innovative approach aims to reverse neurodegeneration and preserve cognitive function in patients, offering a potential breakthrough in Alzheimer's treatment.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.

Autobahn Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing small molecule therapies for central nervous system (CNS) disorders. The company focuses on leveraging its expertise in brain-targeting chemistry to create innovative treatments that harness the regenerative capabilities of the human body. Its primary product candidate, ABX-002, is a thyroid hormone receptor beta agonist aimed at treating multiple sclerosis and adrenomyeloneuropathy, a rare genetic disorder. Founded in 2017, Autobahn Therapeutics is committed to addressing significant unmet medical needs in areas such as neuropsychiatry, neurodegeneration, and neuroinflammation, utilizing validated clinical and biological targets to guide its research and development efforts.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. The company focuses on immuno-oncology, leveraging its unique computational discovery capabilities to identify novel drug targets and biological pathways for cancer therapeutics. Compugen's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT, both designed for the treatment of solid tumors. Additionally, the company has early-stage programs addressing myeloid targets and various mechanisms of immune resistance. Compugen collaborates with notable partners, including Bayer Pharma AG and Bristol-Myers Squibb, to further research and develop its therapeutics. Founded in 1993, Compugen employs a hypothesis-driven approach to drug discovery, utilizing in silico methods for product candidate prediction and validation, enhancing its ability to meet unmet therapeutic needs in the pharmaceutical and biotech sectors.

NIR is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases. IFM Tre was founded in 2017 and headquartered in Boston, Massachusetts.

Avera PACE, a division of Avera Health, operates as a regional group-purchasing organization primarily serving clients in the upper Midwest and across the United States. It focuses on providing access to contracts, services, and products that help businesses, whether located in urban or rural areas, achieve cost savings through collaboration, utilization, and continuous improvement. Avera PACE is part of a broader network that includes Avera Medical Group, which offers a wide range of healthcare services, including behavioral health, cancer care, cardiology, pediatrics, emergency and trauma care, surgery, neuroscience, and women's health.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Jefferson Health System

Akamis Bio is a biotechnology company dedicated to developing innovative gene-based immuno-oncology therapies for cancer treatment. The company focuses on discovering and advancing a range of candidate therapies, including those utilizing its proprietary T-SIGn virus platform, which allows for systemic delivery while exerting localized effects within tumors. Akamis Bio aims to become a leader in cancer gene therapy, emphasizing the importance of creating medicines that provide tangible benefits to patients. The company is actively engaged in both early and clinical stage development of its therapies and seeks to establish strategic partnerships with other leaders in the immuno-oncology field to enhance its product offerings and accelerate the availability of its treatments.

The UNC Center for Aging and Health focuses on delivering high-quality clinical care to older adults while also bridging the gap between families, caregivers, and community resources. The center emphasizes the importance of training not only geriatricians but also a variety of healthcare providers, including dentists, pharmacists, cardiologists, and oncologists, in best practices of geriatric medicine. This training is rooted in research, prioritizes patient needs, and is delivered with compassion. Additionally, as part of the University of North Carolina School of Medicine, the center is committed to improving health and well-being in North Carolina and beyond through excellence in patient care, education, and research, fostering a diverse and respectful environment for faculty, staff, and learners.

IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.

Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.

Cormorant Pharmaceuticals is a privately held, biopharmaceutical company founded by Maarten de Château and Urban Paulsson. The company is based at the Karolinska Institute Science Park in Stockholm, Sweden. Based on mounting research pointing to IL-8 being an important driver of malignant tumors, HuMax-IL8 was acquired from Genmab A/S and taken into development by Cormorant. HuMax-IL8, is a fully human monoclonal antibody

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock was founded by scientists at The Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures. Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company focused on developing therapies for cardiovascular disease. The company specializes in nitroxyl technology, which is aimed at addressing areas of cardiovascular treatment where existing therapies are lacking or ineffective. Cardioxyl has developed a robust portfolio of pre-clinical and clinical candidates, with its lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, a prevalent condition among patients over 65 years of age that often leads to hospitalization. Through its innovative approach, Cardioxyl aims to enhance treatment options for patients suffering from cardiovascular diseases.

Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology. Founded in 2013, Flexus is headquartered in San Carlos, California.

iPierian is engaged in the research and development of therapies aimed at treating neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. The company utilizes induced pluripotent stem cells to facilitate drug discovery and development, focusing on addressing significant unmet medical needs. In particular, iPierian is developing therapies and monoclonal antibodies that target Tauopathies, which are diseases characterized by the accumulation of tau protein in the brain. These therapies aim to slow the spread of tau throughout the brain, thereby inhibiting the progression of associated diseases.

Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Develops a line of diagnostic and therapeutic products for diabetics. Working towards a cure for diabetes by challenging science, changing lives. Amylin employees are dedicated in their ability to "think outside the box". Because of our commitment of constantly finding newer and better ways to treat diabetes, we come to work each day feeling like we CAN make a difference in our world.

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

CareDx is a molecular diagnostics company headquartered in Brisbane, California, established in 2000. It specializes in developing diagnostic assays that leverage advanced genomics technologies to provide clinically actionable insights into a patient's immune status. The company’s flagship product, AlloMap Molecular Expression Testing, is designed for the management of heart transplant patients, aiding in the assessment of transplant rejection. Beyond heart transplants, CareDx is exploring the potential application of its proprietary molecular expression technology for other organ transplants and conditions related to immune system activity, including autoimmune and chronic inflammatory diseases. The company continues to innovate and develop additional products to enhance patient care in transplantation and related fields.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.

ConvaTec has been a pioneer in developing and marketing innovative wound therapeutics and ostomy care products that have helped improve the lives of millions of people worldwide. ConvaTec continues to be at the forefront of the movement to change the way health care professionals are managing chronic and acute wounds, emphasizing the principles of advanced wound healing and evidence-based medicine. From its headquarters in Skillman, New Jersey, the company oversees more than 3,500 employees in 91 countries serving patients and their healthcare professionals on six continents.

ImClone Systems is a leader in the development and manufacture of therapeutic antibodies, focused on advancing oncology care through targeted biologic treatments for various cancers. Established in 1984, the company has cultivated a strong expertise in oncology and utilizes advancements in molecular biology, genomics, and antibody engineering to create a unique pipeline of product candidates aimed at specific genetic mechanisms involved in cancer progression. Besides its marketed product ERBITUX, ImClone is advancing several investigational monoclonal antibodies through various stages of clinical development, targeting major solid tumor types. Following its acquisition by Eli Lilly and Company in 2008, the company has enhanced its antibody pipeline by leveraging Lilly's global resources. ImClone's capabilities are further strengthened by its state-of-the-art, FDA-approved manufacturing facilities in Branchburg, New Jersey, which provide significant capacity for biologic production. The company's research headquarters are located in New York City, and it maintains international operations in Europe, emphasizing its commitment to addressing the medical needs of cancer patients worldwide.

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

DuPont Pharmaceuticals Company engages in the research, development, and delivery of pharmaceuticals that are used in the treatment of HIV, cardiovascular disease, central nervous system disorders, cancer, and inflammatory diseases.

Mead Johnson Nutrition manufactures and sells infant formula, children’s nutrition, and other nutritional products. It offers routine infant formula products as infant’s source of nutrition and supplement to breastfeeding under Enfamil Premium, Enfamil A+, Enfalac Premium, and Enfapro A+ names; and solutions for feeding tolerance problems, including spit-up, fussiness, gas, and lactose intolerance under Enfamil Gentlease, Enfamil A.R., Enfamil ProSobee, and Enfamil LactoFree names. Mead Johnson Nutrition also provides specialty formula products, such as Nutramigen for cow’s milk protein allergies, and Puramino, an amino acid formula for severe cow’s milk protein allergies or other food allergies; Enfamil Premature for premature and low birth weight infants; EnfaCare, a hypercaloric formula for premature babies at home; and medical foods for nutritional management of individuals with rare, inborn errors of metabolism comprising maple syrup urine disease under Mead Johnson BCAD and Mead Johnson Phenyl-Free names. Moreover, Mead Johnson Nutrition offers children’s nutrition products to meet nutritional needs of toddlers and older children under Enfagrow, Sustagen, and Lactum names, as well as milk modifiers under ChocoMilk and Cal-C-Tose names. Further, it provides various other products that comprise pre-natal and post-natal nutritional supplements for expectant and nursing mothers under Expecta and EnfaMama names; pediatric vitamin products that provide multivitamins and iron supplements for infants under Enfamil Poly-Vi-Sol name; and Enfalyte, an oral electrolyte solution for infants and children to replace electrolytes and water to enable restore hydration. Mead Johnson Nutrition markets its products to mothers, health care professionals, and retailers in approximately 50 countries in Asia, North America, Latin America, and Europe. Edward Mead Johnson founded it in 1905, with its headquarters in Glenview in Illinois, now as a subsidiary of Reckitt Benckiser Group.